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Human genetic disease
Coagulation factor deﬁciencyChanges at the invariable donor splice site +1 guanine, relatively frequent in human genetic disease, are pre-
dicted to abrogate correct splicing, and thus are classiﬁed as null mutations. However, their ability to direct
residual expression, which might have pathophysiological implications in several diseases, has been poorly
investigated. As a model to address this issue, we studied the IVS6+1G>T mutation found in patients
with severe deﬁciency of the protease triggering coagulation, factor VII (FVII), whose absence is considered
lethal. In expression studies, the IVS6+1G>T induced exon 6 skipping and frame-shift, and prevented syn-
thesis of correct FVII transcripts detectable by radioactive/ﬂuorescent labelling or real-time RT-PCR. Intrigu-
ingly, the mutation induced the activation of a cryptic donor splice site in exon 6 and production of an in-
frame 30 bp deleted transcript (8±2%). Expression of this cDNA variant, lacking 10 residues in the activation
domain, resulted in secretion of trace amounts (0.2±0.04%) of protein with appreciable speciﬁc activity
(48±16% of wt-FVII). Altogether these data indicate that the IVS6+1G>T mutation is compatible with
the synthesis of functional FVII molecules (~0.01% of normal, 1 pM), which could trigger coagulation.
The low but detectable thrombin generation (352±55 nM) measured in plasma from an IVS6+1G>T
homozygote was consistent with a minimal initiation of the enzymatic cascade. In conclusion, we provide
experimental clues for traces of FVII expression, which might have reverted an otherwise perinatally lethal
genetic condition.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
The relationship between genotype and phenotype in severe
forms of human genetic disease is often elusive because of methodo-
logical limitations in the quantitative evaluation of very low gene ex-
pression levels. While homozygous or compound heterozygous large
gene deletions are unequivocally associated to null genetic condi-
tions, the large majority of molecular defects can potentially account,
through a variety of mechanisms, for residual function.
The process of spontaneous ribosome readthrough over nonsense
mutations, in which the stop codon is mis-recognized by an aminoacyl-
tRNA instead of termination factors [1], can partially restore full-length
protein synthesis and function. This has been shown by us in coagulationistry and Molecular Biology,
Ferrara, Italy. Tel.: +39 0532
-NC-ND license.factor VII (FVII) deﬁciency [2] and by Pacho and co-workers in LAMA3
deﬁciency [3].
Mutations at the completely conserved guanine at the intronic +1
position (Fig. 1A, top) of donor splice sites (5'ss), a relatively frequent
cause of severe human genetic diseases [4], are also generally consid-
ered null mutations as they are predicted to disrupt the splicing pro-
cess [5]. However, for most of them, the complete loss-of-function
feature has not been demonstrated. As a matter of fact, pre-mRNA
splicing is a ﬁnely orchestrated process involving many exonic and
intronic regulatory elements, whose interplay depends on the speciﬁc
gene context [6,7]. Therefore, even mutations at the +1 guanine
might be associated to residual expression levels, as it has been
shown for a +1G>T in intron 2 of Fanconi Anemia C gene [8].
As a disease model to address this issue, we chose the inherited deﬁ-
ciency of FVII [9], which triggers blood coagulation, has the shortest half-
life (3–5 h) and lowest plasma concentration (10 nM) among plasma
serine proteases [10]. The absence of homozygotes for large F7 gene de-
letions (http://www.hgmd.cf.ac.uk; http://www.isth.org/default/index.
cfm/publications/registries-databases/mutations) and the fatal perinatal
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Fig. 1. Characterization of the IVS6+1G>T mutation. (A) Schematic representation of
the F7 gene region interested by the IVS6+1G>T mutation, and cloned as F7minigene
into pcDNA3. The nucleotide sequence of the normal F7 IVS6 5'ss is reported above to-
gether with the donor splice site (5'ss) consensus. The G to T transversion is indicated
by the arrow. The CV of the normal, mutated and exonic cryptic 5'ss, as well as of the
IVS5 and IVS7 5'ss, are reported. (B) Separation on 2% agarose gel of RT-PCR products
obtained from total RNA of cells expressing pIVS6-wt or the pIVS6+1T. The fragment
sizes of the normal (I) and exon 6 skipped (II) transcript forms were 324 bp and
214 bp, respectively. The scheme of transcripts and of primers (arrows) is reported
on the right together with the sequences. M, molecular weight marker.
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indispensable for life, thus rendering residual expression levels associat-
ed to mutations of crucial pathophysiological importance. Not surpris-
ingly, the unique homozygous change affecting the intronic +1G
nucleotide of F7 gene so far described was found to be responsible for a
lethal condition [12].
In this study, we demonstrate that the F7 IVS6+1G>T mutation
(c.681+1G>T; NM-019616.1), found in two homozygous FVII-deﬁcient
patients with life-threatening bleeding symptoms, abrogates correct FVII
mRNA processing but also activates an exonic cryptic 5'ss in cellular
models. This accounts for the secretion of trace amounts of functional
FVII molecules, which could trigger the enzymatic ampliﬁcation pathway
of coagulation.2. Materials and methods
2.1. Patients and functional assays in plasma
F7 mutational screening [13] in FVII-deﬁcient patients referred to
Ramathibodi Hospital in Bangkok identiﬁed two homozygotes
(PFVII-T3, PFVII-T4) for the IVS6+1G>T mutation (Fig. 1A).
PFVII-T3 (female, 21 years old) manifested gastrointestinal and in-
tracranial bleeding at the age of 1 and 3 months, respectively. Subse-
quently, she exhibited several intracranial hemorrhages. She is under
prophylaxis with fresh frozen plasma (FFP) since 1 year of age.
PFVII-T4 (male, 7 year old), presented with severe gastrointestinal
bleeding at 4 and 6 months of age. He is receiving prophylaxis of FFP
three times a week.
Plasma samples, withdrawn upon a ﬁve day wash out replacement
therapy period, was available for PFVII-T3.FVII activity and antigen [14], and thrombin generation [15,16]
levels in plasma were assessed as described.
Formal informed consent for this study was obtained.
2.2. Expression vectors, cell culture and transfection
Expression vectors for the wild-type (pIVS6-wt) and mutant
(pIVS6+1T) minigenes were obtained by polymerase chain reaction
(PCR) ampliﬁcation of the human F7 gene region spanning exons 5
through 7 (1902 bp) from genomic DNA of a IVS6+1G>T carrier
and subsequent cloning into the pcDNA3 plasmid (Fig. 1A).
Expression vector for the FVII-Δ218-227 variant was obtained by
mutagenesis of the human FVII cDNA cloned in pcDNA3 vector [2,14]
by using oligonucleotides 5′ATTGTGGGGGGCAAGGTCCTGTTGTTGGTG3′
and 5′CACCAACAACAGGACCTT GCCCCCCACAAT3′.
The U1+1T snRNA expression vector was prepared as previously
described [17].
All vectors were validated by direct sequencing.
Cell culture and transient transfection of Baby Hamster Kidney
(BHK) cells were conducted as described [2,14].
2.3. Reverse transcription (RT), PCR and quantitative RT-PCR
Reverse transcription (RT), PCR and quantitative RT-PCR,
were conducted as described [13,17,18] using the forward primers
5F (5′GAGAACGGCGGCTGTGAG3′) and 6F (5′GTTCCTCCAGTTCTTGA
TTTTGTCG3′) and the reverse primers 7R (5′GTTCCTCCAGTTCTTGATT
TTGTCG3′) or 7R-FAM (5′cgacaCCAGTTCTTGATTTT GTcG3′).
For quantitative PCR (qPCR), primers 5F and 7R were used to am-
plify all FVII transcripts whereas primers 5F and 6/7R (5′ACCAACAA-
CAGGACCTGCCA3′), targeting the exon 6–7 junction, were exploited
to amplify those including exon 6.
2.4. Measurement of secreted FVII protein and activity levels in conditioned
media
Evaluation of secreted FVII protein levels by ELISA was conducted
as described [2,14]. Besides the standard curve with a serial dilution
of pooled normal plasma (PNP), a reference curve with a serial dilu-
tion of recombinant Wt-FVII in conditioned media was made. The de-
tection limit of the ELISA was 1 ng/ml FVII.
For Western blotting analysis, conditioned mediumwas incubated
5 min at 95 °C and run on 4–12% SDS-PAGE (NuPAGE Bis-Tris gel,
Invitrogen ®; Carlsbad, CA). Proteins were transferred onto a 0.2 μm
nitrocellulose membrane (Whatman®, Dassel, Germany), which
was blocked overnight with PBS buffer supplemented with 0.1%
Tween-20 (PBS-T) and 5% low fat dry milk (Bio-Rad, Hercules, CA).
Membranes were then incubated for 4 h at room temperature with
the anti-human FVII HRP-conjugated antibody (Pierce® Factor VII
(HRP) Polyclonal Sheep, 2 mg/ml, Thermo Scientiﬁc, Rockford, IL,
USA) diluted 1:2500 in blocking buffer. The Supersignal® West
Femto reagent (Thermo Scientiﬁc, Rockford, IL) was exploited for de-
tection. The FVII protein puriﬁed from human plasma (pdFVII) was
purchased from Haematologic Technologies Inc (Essex Junction, VT,
USA) at the concentration of 2.6 mg/ml. Upon dilution, it was used
as reference in our experiments.
The activity of FVII variants toward its natural FVII substrate, factor X
(FX), was evaluated in plasma systems by adding recombinant FVII to
FVII-deﬁcient plasma (George King, Bio-Medical Inc., USA). Generation
of activated FX (FXa) was monitored over time by exploiting a spe-
ciﬁc FXa ﬂuorogenic substrate (MeSO2-D-CHA-Gly-Arg-AMCAcOH;
American Diagnostica Inc., Greenwich, CT, USA)[14].
Serial dilutions of rFVII-wt were used to optimize the assay that, in
our hand, enabled the detection of the activity produced by as low as
0.15 ng/ml of Wt-FVII.
U1+1T
A
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vector were used as negative control in all assays.
3. Results and discussion
In this study, we investigated the IVS6+1G>T mutation in the
5'ss of F7 intron 6 (Fig. 1A), which was found to be associated to
life-threatening bleeding in two homozygous patients (PFVII-T3,
PFVII-T4).
The IVS6+1G>T mutation was also found in doubly heterozy-
gous condition with the W424X nonsense mutation [2], in a severe
patient who experienced intracranial bleeding, or the C389G substi-
tution, in a mildly affected patient.
The IVS6+1G>T mutation in PFVII-T3 and PFVII-T4 was associat-
ed to a very severe coagulation phenotype characterized by undetect-
able FVII protein plasma levels (b0.5% of pooled normal plasma),
which did not correspond to any measurable coagulant activity.
Altogether these data in vivo are consistent with the extreme deﬁ-
ciency of circulating FVII caused by the IVS6+1G>T change.
3.1. Aberrant FVII splicing patterns associated to the IVS6+1G>T
mutation
To investigate the residual FVII expression associated to the IVS6+
1G>T mutation, if any, we focused the study on the mRNA level,
which takes advantage of highly sensitive ampliﬁcation techniques.
Since investigation of FVII splicing patterns in patient's liver, the physi-
ological site of expression, or in extra-hepatic tissues, was not feasible,
splicing mechanisms were sought by expressing the normal (pIVS6-
wt) and mutated (pIVS6+1T) F7 minigenes in mammalian cells. This
approach has been successfully exploited to study splicing mutations
in F7 [13,19] as well as in many other human disease genes [8,20,21].
The splicing patterns observed in vitromirrored those detected in avail-
able patient's tissues [8,13,20].
While the expression of pIVS6-wt produced correctly processed
FVII transcripts, the pIVS6+1T drove the synthesis of a FVII mRNA
lacking exon 6 (Fig. 1B, form II), frame-shifted from codon 190 and
not compatible with measurable FVII levels in plasma.
The presence of correct FVII transcripts associated to the IVS6+
1G>T mutation were evaluated by labelling of RT-PCR products
(Fig. 2A). Denaturing capillary electrophoresis of ﬂuorescently labelledFig. 2. Investigation of residual levels of correctmRNA forms. (A) Separation on a denatur-
ing capillary system (automated ABI-3100) of ﬂuorescently labelled RT-PCR products (1 μl
of 1:100 diluted reaction) obtained from total RNA of cells expressing pIVS6-wt (top) or
the pIVS6+1T. The fragment sizes of the normal (I) and exon 6 skipped (II) transcript
forms were 324 bp and 214 bp, respectively. The magniﬁed lower panel highlights the
30 bp deleted FVII transcript (III; asterisk). The inset in the upper panel reports a magni-
ﬁed view of the chromatogram.The scheme of transcripts and of primers (arrows) is
depicted at the bottom. (B) Radioactively labelled RT-PCR products (12% polyacrylamide
gel). The normal (I) and the 30 bp deleted (III; asterisk) FVII transcripts are indicated.
The scheme of transcripts and of primers (arrows) is reported at the bottom together
with the sequence of the 30 bp deleted transcript.RT-PCR fragments, even upon column overloading, did not reveal nor-
mal FVII mRNA forms (form I, 324 bp).
Neither radioactive labelling of RT-PCR products (Fig. 2B) nor qRT-
PCR revealed normal transcripts. Remarkably, the exon 6 skipped
transcripts were still detectable upon a 1:10,000 dilution, thus sug-
gesting that, if present, the levels of correct FVII transcripts associated
to the mutation were below the 0.01% of the aberrant ones.
In the earliest splicing step, the donor splice site is recognized by
the spliceosomal small nuclear ribonucleoprotein U1-snRNP [22],
and particularly by its RNA component (U1-snRNA). It has been dem-
onstrated that U1-snRNA variants engineered to restore the comple-
mentarity with defective donor splice sites can re-direct splicing to
the correct junction [17,21,23]. Although mutations that disrupt the
invariant GT dinucleotide of 5'ss are usually not rescued [23], the
c.165+1G>T mutation in the FANCC gene was successfully treated
[8]. It must be noticed that in the latter case, the +1G>T change
does not completely abrogate splicing and it is compatible with syn-
thesis of correct transcripts.
To further exclude the possibility that the IVS6+1G>T in F7 gene
also creates a leaky 5'ss, we designed and created a modiﬁed U1-
snRNA (U1+1T) targeting the mutated IVS6 5'ss (Fig. 3A). Even
upon over-expression, the U1+1T failed to produce traces of normal
FVII mRNA (Fig. 3B). Since the mutation-speciﬁc U1+1T did not re-
store normal splicing, we infer that the IVS6+1G>T mutation likely
affects subsequent steps of the splicing process.
Although the production of trace levels of correct transcripts in pa-
tients’ liver cannot be completely excluded, the overall data support
the abrogation of the IVS6 donor splice site by the IVS6+1G>T change.
We sought for the presence of alternative splicing patterns, able to
rescue FVII expression and prevent perinatal lethality. Chromatograms
(Fig. 2A) and ﬁlms (Fig. 2B) identiﬁed an additional FVII transcript (8±
2% of exon 6 skipped forms) in pIVS6+1T expressing cells. Sequencing
of nested-PCR products, with primers 6F and 7R, to avoid ampliﬁcation
of the abundant exon 6 skipped forms (Fig. 2B) revealed the presence
of a 30 bp deleted mRNA originating from usage of a cryptic 5'ss in
exon 6 (Fig. 1A). Differently, the cryptic site was silent in the pIVS6-wt
context, as indicated by the undetectable levels of the 30 bp deletedB
0x 1x 2x 3x 0x 3x U1+1T
I
II
pIVS6+1T pIVS6-wt
5F 7R5F 7R
Ex6Ex5 Ex7Ex5 Ex7
Fig. 3. Effect of themutation-speciﬁc U1+1 T snRNA on FVII mRNA splicing. (A) Schematic
representation of the exon 6–intron 6 splicing junction and of the U1-snRNA secondary
structure. The 5′ tail of U1-snRNAs was engineered to bind to the mutated IVS6 5'ss, and
their sequence complementary is shown. (B) RT-PCR products from cells expressing the
pIVS6-wt and pIVS6+1T upon cotransfection with increasing molar amounts (0–3×) of
the mutation-speciﬁc pU1+1T (2% agarose gel). The scheme of transcripts (I, II and III as
in Fig. 1C), and of primers (arrows), is depicted at the bottom.
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radioactive labelling (Fig. 2B). These results were consistent with the
consensus value (CV) of F7 5'ss predicted by computational analysis
(www.fruitﬂy.org). In particular, the cryptic site in exon 6 (CV 0.76)
was used when the canonical 5'ss, the strongest (CV 1.0) among all ca-
nonical 5'ss of F7 gene (average CV 0.86), is abrogated by the IVS6+
1G>Tmutation (CV 0.0) (Fig. 1A). Noticeably, the CV of the exon 6 cryp-
tic 5'ss is, within the mutated allele, the highest in the F7 gene region
spanning exon 5 through 7. Computational analysis also revealed an ad-
ditional potential 5'ss (CV 0.56) in intron 6 at position +92, which was
not used in any of the experimental conditions tested.3.2. Expression of the in-frame deleted FVII mRNA accounts for residual
function
The 30 bp in-frame deleted FVII mRNA would encode for a protein
lacking 10 residues (Val218-Gln227; chymotrypsin numbering
21–30) in the activation domain of the serine protease (Fig. 4A).
The deletion removes an intra-chain disulphide bridge (Cys219–
Cys224), but not the Arg212-Ile213 activation site. Remarkably, in
the zymogen (PDB ID: 1JBU) or in the activated (PDB ID: 1QFK) FVII
crystallographic structures the deleted residues belong to a surface
exposed loop (Fig. 4B) that is present in all serine proteases [24].
However, its primary sequence is, with the exception of the proline
225 (c23), moderately degenerated. Expression studies were under-
taken to assess whether the deletion of this region was compatible
with FVII secretion and function. Upon an 8X concentration of condi-
tioned medium, the recombinant FVIIΔ218-227 variant was detect-
able by ELISA (2 ng/ml) and Western blotting (Fig. 4C).
The assessment of its activity, which is essential to evaluate the re-
sidual coagulant properties, was carried out by functional assays withEx.5 Ex.6 Ex.7*
A
K
Cleavage 
site
s s
N - Terminus CatalyticDomain
*
FVII Δ218 - 227
R212 I213
V
B
r 218-227rWtpdFVII NC
Loop
218-227
(c21-30)
H193
D242
S344
FVIIa
Heavychain
FVIIa
Lightchain
C
Δ
Fig. 4. Residual protein and activity levels of the FVII Δ218-227 variant. (A) Schematic
representation of (upper panel) the splicing events observed in the wt (dotted line) or
in the IVS6+1G>T mutant (bold dotted line), and of (lower panel) the deleted FVII
Δ218-227 variant. The asterisk indicates the 5'ss cryptic site or the in-frame K217-V228
junction. (B) Strand diagram showing three-dimensional structure of human activated
FVII. The deleted region of the activation domain is highlighted in black whereas the cat-
alytic triad is reported in ball-and-stick. This is a RasMol presentation of ﬁle1QFK from the
Brookhaven Protein Data Bank. (C) FVII protein (WB, left panel), antigen (ELISA, middle
panel) and speciﬁc activity (right panel) levels in conditioned medium from cells expres-
sing the rFVII-wt or the rFVII Δ218-227 variants, or transfected with the empty pcDNA3
(NC). Conditioned media were concentrated through the Amicon Ultra centrifugal ﬁlter
devices (cut-off 30 kDa, Millipore, Carrigtwohill, County Cork, Ireland). For Western blot-
ting analysis, the rFVII-wt was loaded at a concentration (4 ng/ml) comparable to that of
the rFVIIΔ218-227 variant. The plasma derived FVII (pdFVII) was loaded as control at the
concentration of 4 ng/ml.To assess the speciﬁc activity, ﬂuorogenic FXa generation assays
were conducted in FVII depleted plasma supplementedwith rFVII-wt or of rFVIIΔ218-227.
Results, obtained in three independent experiments conducted in duplicate, are expressed
as % of the relative rFVII-wt.the recombinant protein added to FVII-deﬁcient plasma, to better
mimic the physiological conditions. In these assays, we measured
the activity of FVII toward its physiologic substrate, factor X (FX), by
exploiting a ﬂuorogenic substrate for activated FX, which permits
high sensitivity to very low activity levels [2,14]. Interestingly, the
speciﬁc activity of the deleted FVII resulted to be approximately half
of that of the rFVII-wt (48±16%) (Fig. 4C), thus indicating that the
deletion in the activation domain is compatible with FVII activation
and catalytic function. Among the over 250 mutations so far reported
in FVII deﬁciency (http://www.hgmd.cf.ac.uk), none was identiﬁed in
this region, thus further supporting our observation.
3.3. Residual coagulation function in plasma from the IVS6+1G>T
homozygous patient
A thumbnail calculation based on the results from the mRNA (~8%
of skipped transcript) and functional protein (~0.1% of normal) stud-
ies predicts that the IVS6+1G>T mutation produces approximately
0.01% of functional FVII as compared to the normal. Both empirical
and mathematical modelling studies suggested that this concentra-
tion should be sufﬁcient to induce coagulation [25]. Therefore, we
evaluated the coagulation cascade efﬁciency in plasma from the
IVS6+1G>T homozygote (PFVII-T3) by the real-time measurement
of the generation of thrombin, the last effector of the coagulation cas-
cade [15]. This assay, albeit with the limitations of a global assay in
testing the inﬂuence of a single protein, takes advantage of the ampli-
ﬁcation features of the pathway and might unravel the functional im-
pact of even very low FVII activity, far below the direct detection limit
in plasma.
Intriguingly, upon coagulation triggering with tissue factor, the
obligatory cofactor of FVII [26], the thrombin generation activity in plas-
ma from patient PFVII-T3 was appreciable (352±55 nM)(Fig. 5). This
extent of thrombin generation was smaller than in plasma from a pa-
tient homozygous for the nonsense mutation K376X (630±20 nM)
that accounts for residual FVII function by the mechanism of ribosome
readthrough [2].
Taken together these data support the association of the IVS6+
1G>T mutation with the lowest FVII function ever described in FVII
deﬁciency.
3.4. Conclusions
Overall data at the mRNA and protein level highlight poorly recog-
nized mechanisms and effects of aberrant splicing. The IVS6+1G>T
change, because of the favourable gene sequence context—i.e. pres-
ence of an in-frame cryptic donor splice site—abrogates correct splic-
ing but also induces the synthesis of an in-frame alternative FVII
transcript. This mRNA encodes for a protein that is scarcely secreted
but, due to a favourable protein context—a poorly conserved se-
quence in the activation domain of serine proteases—possesses aFig. 5. Thrombin generation activity in plasma from the PFVII-T3.Thrombin generation
curves in plasma from the IVS6+1G>T (PFVII-T3) and the K376X homozygotes, and
in the commercial FVII-deﬁcient plasma (DP, George King, Bio-Medical Inc., USA).
The Extrinsic Thrombin Potential in the different plasma samples is reported in the his-
togram and is expressed as nM thrombin.
1113N. Cavallari et al. / Biochimica et Biophysica Acta 1822 (2012) 1109–1113remarkable catalytic activity. The in silico splicing pattern prediction,
the coherent results from expression studies and thrombin genera-
tion in patient's plasma make this aberrant splicing event likely to
occur in vivo. These mechanistic features are compatible with traces
of FVII expression, among the lowest levels reported in human dis-
eases. Being FVII the enzyme triggering the ampliﬁcation cascade pro-
cess, its residual expression might ensure a minimal hemostasis and
reverted an otherwise perinatally lethal genetic condition.
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